NASDAQ:ARNA
Delisted
Arena Pharmaceuticals Stock News
$99.99
+0 (+0%)
At Close: May 27, 2022
The Daily Biotech Pulse: Kodiak Sinks On Adverse Study Outcome, Marinus Flags Delay In Clinical Trial, Mainz Biomed Gains On Positive Regulatory Development
01:01pm, Wednesday, 23'rd Feb 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours.
Stocks In Focus
Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase 2b/3 Study
Kodiak Sciences
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
01:06pm, Sunday, 20'th Feb 2022 Benzinga
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries.
On the regulatory front, the Food and Drug A
Top 3 weed stocks to put on your watch list this year
07:30pm, Thursday, 17'th Feb 2022
The marijuana industry has seen sharp growth year on year.
Why Investors Aren't Worried About Pfizer's Latest Failure
12:00pm, Tuesday, 15'th Feb 2022 The Motley Fool
Is this discontinued drug from Pfizer nothing more than a drop in the bucket?
Expert Ratings For Arena Pharmaceuticals
03:21pm, Wednesday, 09'th Feb 2022 Benzinga
Arena Pharmaceuticals (NASDAQ: ARNA ) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 1 7 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 6 0 0 3M Ago 0 1 0 0 0 In the last 3 months, 8 analysts have offered 12-month price targets for Arena Pharmaceuticals. The company has an average price target of $96.38 with a high of $100.00 and a low of $71.00. Below is a summary of how these 8 analysts rated Arena Pharmaceuticals over … Full story available on Benzinga.com
Benzinga's Top Ratings Upgrades, Downgrades For February 9, 2022
03:02pm, Wednesday, 09'th Feb 2022 Benzinga
Upgrades
According to Capital One, the prior rating for Federal Realty Investment Trust (NYSE:FRT) was changed from Equal-Weight to Overweight. Federal Realty Investment earned $1.51 in the third qua
Did The Smart Money Play Arena Pharmaceuticals, Inc. (ARNA) Correctly?
09:25pm, Sunday, 06'th Feb 2022 Insider Monkey
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 867 13F filings that hedge funds and well-known value investors are required to file by the SEC.
Is a Beat Likely for Pfizer (PFE) This Earnings Season?
04:56pm, Wednesday, 02'nd Feb 2022 Zacks Investment Research
Higher sales of Pfizer's (PFE) key brands, Eliquis (alliance revenue), Xtandi and Inlyta, and revenues from the COVID-19 vaccine are likely to have driven sales in the fourth quarter.
Merger Arbitrage Mondays - Activision Blizzard Trades At A Big Discount To Microsoft's Acquisition Price
05:16am, Tuesday, 25'th Jan 2022 Seeking Alpha
Microsoft acquires Activision (ATVI) in a $68.7 billion deal. MSFT expects to strengthen its gaming presence and enter the metaverse with strong franchises.
3 Clinical Trials to Watch in the First Half of 2022
01:46pm, Saturday, 22'nd Jan 2022 The Motley Fool
These clinical studies don't just impact the companies conducting them.
3 Dividend Stocks to Buy if the Market Crashes
10:55am, Friday, 21'st Jan 2022 The Motley Fool
All three of these stocks share a key attribute: resiliency.
Pharma Giants Go After $10 Billion Market With RSV Drugs
04:33pm, Tuesday, 18'th Jan 2022
GlaxoSmithKline PLC ( GSK , Financial), Pfizer Inc. ( PFE , Financial) and Johnson & Johnson ( JNJ , Financial) should all know about mid-year if the shots they're developing for a common and potentia
Arena (ARNA) Stock Up in 6 Months on PFE Merger Deal & Pipeline
03:24pm, Tuesday, 18'th Jan 2022 Zacks Investment Research
Arena Pharmaceuticals' (ARNA) potential acquisition by Pfizer to enable it to advance the development of its pipeline, especially the company's lead candidate, etrasimod, for ulcerative colitis.
Arena Pharmaceuticals Inc Shares Close in on 52-Week High - Market Mover
06:45am, Monday, 17'th Jan 2022 Kwhen Finance
Arena Pharmaceuticals Inc (ARNA) shares closed today at 1.7% below its 52 week high of $94.23, giving the company a market cap of $5B. The stock is currently down 0.3% year-to-date, up 15.1% over the past 12 months, and up 552.5% over the past five years. This week, the Dow Jones Industrial Average fell 0.9%, and the S&P 500 fell 0.3%. Trading Activity Trading volume this week was 10.9% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.
Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -94.3% The company's stock price performance over the past 12 months beats the peer average by -144.9%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.
Arena Pharmaceuticals Inc Shares Close in on 52-Week High - Market Mover
12:03pm, Thursday, 13'th Jan 2022 Kwhen Finance
Arena Pharmaceuticals Inc (ARNA) shares closed today at 1.5% below its 52 week high of $94.23, giving the company a market cap of $5B. The stock is currently down 0.2% year-to-date, up 20.5% over the past 12 months, and up 539.8% over the past five years. This week, the Dow Jones Industrial Average fell 1.4%, and the S&P 500 fell 1.6%. Trading Activity Trading volume this week was 35.5% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.6. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.
Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -96.1% The company's stock price performance over the past 12 months beats the peer average by -158.8%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.